Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection

Tetyana Buzhdygan, Joshua Lisinicchia, Vipulkumar Patel, Kenneth Johnson, Volker Neugebauer, Slobodan Paessler, Kristofer Jennings, Benjamin Gelman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The prevalence of HIV-associated neurocognitive disorders (HAND) remains high in patients with effective suppression of virus replication by combination antiretroviral therapy (cART). Several neurotransmitter systems were reported to be abnormal in HIV-infected patients, including the inhibitory GABAergic system, which mediates fine-tuning of neuronal processing and plays an essential role in cognitive functioning. To elucidate the role of abnormal GABAergic transmission in HAND, the expression of GABAergic markers was measured in 449 human brain specimens from HIV-infected patients with and without HAND. Using real-time polymerase chain reaction, immunoblotting and immunohistochemistry we found that the GABAergic markers were significantly decreased in most sectors of cerebral neocortex, the neostriatum, and the cerebellum of HIV-infected subjects. Low GABAergic expression in frontal neocortex was correlated significantly with high expression of endothelial cell markers, dopamine receptor type 2 (DRD2L), and preproenkephalin (PENK) mRNAs, and with worse performance on tasks of verbal fluency. Significant associations were not found between low GABAergic mRNAs and HIV-1 RNA concentration in the brain, the history of cART, or HIV encephalitis. Pathological evidence of neurodegeneration of the affected GABAergic neurons was not present. We conclude that abnormally low expression of GABAergic markers is prevalent in HIV-1 infected patients. Interrelationships with other neurotransmitter systems including dopaminergic transmission and with endothelial cell markers lend added support to suggestions that synaptic plasticity and cerebrovascular anomalies are involved with HAND in virally suppressed patients.

Original languageEnglish (US)
Pages (from-to)279-293
Number of pages15
JournalJournal of NeuroImmune Pharmacology
Volume11
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

HIV Infections
HIV
Neocortex
Neurotransmitter Agents
HIV-1
Endothelial Cells
Neostriatum
GABAergic Neurons
Messenger RNA
Neuronal Plasticity
Dopamine Receptors
Brain
Task Performance and Analysis
Encephalitis
Virus Replication
Immunoblotting
Cerebellum
Real-Time Polymerase Chain Reaction
History
Immunohistochemistry

Keywords

  • Autopsy
  • GABA
  • GABAergic
  • Glutamate decarboxylase
  • HIV associated neurocognitive disorders
  • HIV encephalitis

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy
  • Immunology
  • Neuroscience (miscellaneous)

Cite this

Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection. / Buzhdygan, Tetyana; Lisinicchia, Joshua; Patel, Vipulkumar; Johnson, Kenneth; Neugebauer, Volker; Paessler, Slobodan; Jennings, Kristofer; Gelman, Benjamin.

In: Journal of NeuroImmune Pharmacology, Vol. 11, No. 2, 01.06.2016, p. 279-293.

Research output: Contribution to journalArticle

Buzhdygan, Tetyana ; Lisinicchia, Joshua ; Patel, Vipulkumar ; Johnson, Kenneth ; Neugebauer, Volker ; Paessler, Slobodan ; Jennings, Kristofer ; Gelman, Benjamin. / Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection. In: Journal of NeuroImmune Pharmacology. 2016 ; Vol. 11, No. 2. pp. 279-293.
@article{b2ded1bc77434256b0538555f7d03f54,
title = "Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection",
abstract = "The prevalence of HIV-associated neurocognitive disorders (HAND) remains high in patients with effective suppression of virus replication by combination antiretroviral therapy (cART). Several neurotransmitter systems were reported to be abnormal in HIV-infected patients, including the inhibitory GABAergic system, which mediates fine-tuning of neuronal processing and plays an essential role in cognitive functioning. To elucidate the role of abnormal GABAergic transmission in HAND, the expression of GABAergic markers was measured in 449 human brain specimens from HIV-infected patients with and without HAND. Using real-time polymerase chain reaction, immunoblotting and immunohistochemistry we found that the GABAergic markers were significantly decreased in most sectors of cerebral neocortex, the neostriatum, and the cerebellum of HIV-infected subjects. Low GABAergic expression in frontal neocortex was correlated significantly with high expression of endothelial cell markers, dopamine receptor type 2 (DRD2L), and preproenkephalin (PENK) mRNAs, and with worse performance on tasks of verbal fluency. Significant associations were not found between low GABAergic mRNAs and HIV-1 RNA concentration in the brain, the history of cART, or HIV encephalitis. Pathological evidence of neurodegeneration of the affected GABAergic neurons was not present. We conclude that abnormally low expression of GABAergic markers is prevalent in HIV-1 infected patients. Interrelationships with other neurotransmitter systems including dopaminergic transmission and with endothelial cell markers lend added support to suggestions that synaptic plasticity and cerebrovascular anomalies are involved with HAND in virally suppressed patients.",
keywords = "Autopsy, GABA, GABAergic, Glutamate decarboxylase, HIV associated neurocognitive disorders, HIV encephalitis",
author = "Tetyana Buzhdygan and Joshua Lisinicchia and Vipulkumar Patel and Kenneth Johnson and Volker Neugebauer and Slobodan Paessler and Kristofer Jennings and Benjamin Gelman",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s11481-016-9652-2",
language = "English (US)",
volume = "11",
pages = "279--293",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection

AU - Buzhdygan, Tetyana

AU - Lisinicchia, Joshua

AU - Patel, Vipulkumar

AU - Johnson, Kenneth

AU - Neugebauer, Volker

AU - Paessler, Slobodan

AU - Jennings, Kristofer

AU - Gelman, Benjamin

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The prevalence of HIV-associated neurocognitive disorders (HAND) remains high in patients with effective suppression of virus replication by combination antiretroviral therapy (cART). Several neurotransmitter systems were reported to be abnormal in HIV-infected patients, including the inhibitory GABAergic system, which mediates fine-tuning of neuronal processing and plays an essential role in cognitive functioning. To elucidate the role of abnormal GABAergic transmission in HAND, the expression of GABAergic markers was measured in 449 human brain specimens from HIV-infected patients with and without HAND. Using real-time polymerase chain reaction, immunoblotting and immunohistochemistry we found that the GABAergic markers were significantly decreased in most sectors of cerebral neocortex, the neostriatum, and the cerebellum of HIV-infected subjects. Low GABAergic expression in frontal neocortex was correlated significantly with high expression of endothelial cell markers, dopamine receptor type 2 (DRD2L), and preproenkephalin (PENK) mRNAs, and with worse performance on tasks of verbal fluency. Significant associations were not found between low GABAergic mRNAs and HIV-1 RNA concentration in the brain, the history of cART, or HIV encephalitis. Pathological evidence of neurodegeneration of the affected GABAergic neurons was not present. We conclude that abnormally low expression of GABAergic markers is prevalent in HIV-1 infected patients. Interrelationships with other neurotransmitter systems including dopaminergic transmission and with endothelial cell markers lend added support to suggestions that synaptic plasticity and cerebrovascular anomalies are involved with HAND in virally suppressed patients.

AB - The prevalence of HIV-associated neurocognitive disorders (HAND) remains high in patients with effective suppression of virus replication by combination antiretroviral therapy (cART). Several neurotransmitter systems were reported to be abnormal in HIV-infected patients, including the inhibitory GABAergic system, which mediates fine-tuning of neuronal processing and plays an essential role in cognitive functioning. To elucidate the role of abnormal GABAergic transmission in HAND, the expression of GABAergic markers was measured in 449 human brain specimens from HIV-infected patients with and without HAND. Using real-time polymerase chain reaction, immunoblotting and immunohistochemistry we found that the GABAergic markers were significantly decreased in most sectors of cerebral neocortex, the neostriatum, and the cerebellum of HIV-infected subjects. Low GABAergic expression in frontal neocortex was correlated significantly with high expression of endothelial cell markers, dopamine receptor type 2 (DRD2L), and preproenkephalin (PENK) mRNAs, and with worse performance on tasks of verbal fluency. Significant associations were not found between low GABAergic mRNAs and HIV-1 RNA concentration in the brain, the history of cART, or HIV encephalitis. Pathological evidence of neurodegeneration of the affected GABAergic neurons was not present. We conclude that abnormally low expression of GABAergic markers is prevalent in HIV-1 infected patients. Interrelationships with other neurotransmitter systems including dopaminergic transmission and with endothelial cell markers lend added support to suggestions that synaptic plasticity and cerebrovascular anomalies are involved with HAND in virally suppressed patients.

KW - Autopsy

KW - GABA

KW - GABAergic

KW - Glutamate decarboxylase

KW - HIV associated neurocognitive disorders

KW - HIV encephalitis

UR - http://www.scopus.com/inward/record.url?scp=84964792454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964792454&partnerID=8YFLogxK

U2 - 10.1007/s11481-016-9652-2

DO - 10.1007/s11481-016-9652-2

M3 - Article

C2 - 26829944

AN - SCOPUS:84964792454

VL - 11

SP - 279

EP - 293

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 2

ER -